ESR1 and breast neoplasm: In addition, studies utilizing ER+ breast tumor cells that have developed resistance to tamoxifen, fulvestrant, and/or palbociclib are needed to extend this work to the clinical situation, where drug resistance often compromises the effectiveness of antiestrogen therapies.